Moreover, corroborating CyTOF data (Figure 3, B and C), FOXP3, LRRC32, TNFRSF18, HLA-DR, and CD27 mean mRNA expression was increased in Treg populations in the majority of the participants after ld-IL-2 treatment at day 7 and day 42 (Figure 4D; upper graphs) when compared with samples from patients in the Treg-T1D trial (Figure 4D, lower graphs). The gene discussed is LRRC32; the disease is type 1 diabetes mellitus.